|Day's Range||129.22 - 133.61|
|52 Week Range||110.90 - 169.89|
|PE Ratio (TTM)||9.30|
|Earnings Date||Jul 27, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||125.18|
Value investing is by nature contrarian and the underperformance of value stocks over the past few years could be a opportunity for long-term disciplined investors. Here are some of the deepest value stocks in the market using the strategy of legendary investor Ben Graham.
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , July 21, 2017 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will report its second quarter 2017 financial ...
Oppenheimer's Hartaj Singh reitearted his bullish stance on United Therapeutics ( UTHR) on Wednesday, writing that upcoming catalysts in the next six to 12 months are critical to the stock, and, if they go well, could lead to it re-rating. The most important catalyst may be the FREEDOM-EV Phase 3 pivotal trial of Orenitram in pulmonary arterial hypertension.